None listed
Conditions
Brief summary
This study will compare the ‘best possible’ treatment delivered during the COVID-19 pandemic to ‘ideal’ treatment before the pandemic for newly diagnosed early breast cancer patients Who is it for? You may be eligible to join this study if you are aged 18 and above, have been newly diagnosed with early breast cancer at Westmead Breast Cancer Institute during the COVID-19 pandemic and discussed by the Westmead multidisciplinary cancer team (MDT) between March and June 2020. Study details MDTs, consisting of surgeons, medical oncologists, radiation oncologists, pathologists, breast physicians, genetic oncologists and other specialty representatives, will discuss and assess participants’ ‘ideal’ and ‘best possible’ treatment options at team meetings. All participants assessed by an MDT will have discussions about the ‘ideal’ and ‘best possible’ treatment with their treating specialist. The reasons for any treatment that varies from ideal will be explained to the participant. When the COVID-19 pandemic finishes, the participant will be recalled to discuss further treatment if their treatment differed from the 'ideal.' At various stages of treatment, the MDTs will meet and assess participants’ treatment options. All discussions and treatment delivered will be documented in medical records. It is hoped that this research will give insight into the challenges that the COVID-19 pandemic has presented for breast cancer treatment. It will also identify participants who have not had ideal treatment and they can be followed closely in the future.
Interventions
This project will compare the ‘ideal, evidence-based treatment’ that would have been delivered pre-COVID to the care that is actually delivered, given the restrictions, during the COVID pandemic. The multidisciplinary team will document the recommended treatment (COVID-restricted) for each patient that is discussed. At the same time, the team will document what the 'ideal' treatment would have been without COVID restrictions.
This is an observational trial, so no action is required from partici
This project will compare the ‘ideal, evidence-based treatment’ that would have been delivered pre-COVID to the care that is actually delivered, given the restrictions, during the COVID pandemic. The multidisciplinary team will document the recommended treatment (COVID-restricted) for each patient that is discussed. At the same time, the team will document what the 'ideal' treatment would have been without COVID restrictions. This is an observational trial, so no action is required from participants. Participants will be informed of the ideal treatment and the changes resulting from COVID restrictions. This will be documented and discussed with the participant each time their case is discussed by the MDT. On average, this is once or twice, depending on the sequencing of treatment and complexity of the case. Cases treated according to 'ideal' management will not be followed-up. Those receiving treatment altered by the pandemic will be identified by this study and followed-up at 3-monthly intervals until this is deemed no longer needed according to MDT recommendations.
Sponsors
Westmead Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
All new cases of early breast cancer presenting to WBCI and discussed through one of the three multidisciplinary cancer teams (MDTs) will be included.
Exclusion criteria
1. Cases of advanced (metastatic) breast cancer. 2. Cases of locally recurrent breast cancer.
Outcome results
None listed